Drug Profile
Cupressus arizonica pollen allergy immunotherapy - ALK-Abello
Alternative Names: Arizona cypress pollen allergy immunotherapy; AVANZ Cupressus; Cupressus pollen allergy immunotherapy; Polen de Cupressus arizonica immunotherapyLatest Information Update: 15 Dec 2016
Price :
$50
*
At a glance
- Originator ALK-Abello
- Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allergic rhinoconjunctivitis
Most Recent Events
- 25 Nov 2016 Launched for Allergic rhinoconjunctivitis in Spain before November 2016 (SC) (ALK-Abello email communication)
- 01 Nov 2014 ALK-Abello completes a phase II trial in Allergic rhinoconjunctivitis in Spain (NCT02069535)
- 28 Aug 2014 CTP push (NCT02069535)- now recruiting, removed EudraCT2013-001728-20 from profile as this record no longer contains info related to Cupressus immunotherapy (RDI 39488), changed phase date to match NCT02069535 & changed phase from II/III to II as per NCT and updated Eudra record